𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Human agmatinase is diminished in the clear cell type of renal cell carcinoma

✍ Scribed by Kerstin Dallmann; Heike Junker; Stefan Balabanov; Uwe Zimmermann; Jürgen Giebel; Reinhard Walther


Publisher
John Wiley and Sons
Year
2003
Tongue
French
Weight
299 KB
Volume
108
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The proteome of RCC was analyzed by 2D PAGE to search for tumor‐associated proteins. Agmatinase, which hydrolyzes agmatine to putrescine and urea, was identified by mass spectrometry and database searches and shown to be downregulated in tumor cells. Additionally, RT‐PCR and Northern blot analyses demonstrated a clearly decreased amount of agmatinase mRNA in tumor cells. The differential expression of agmatinase mRNA was confirmed at the protein level. Western blot analysis showed almost no detectable agmatinase protein in tumor cells compared to corresponding normal renal tissue. Agmatinase mRNA is most abundant in human liver and kidney but expressed to a lesser extent in several other tissues, including skeletal muscle and small intestine. The human agmatinase gene encodes a 352‐residue protein with a putative mitochondrial targeting sequence at the N‐terminus. Using transfection and immunohistochemical studies, we show that agmatinase is localized in the mitochondria. Immunohistochemical studies revealed that agmatinase in the normal kidney is restricted to tubulus epithelial cells, while in tumors staining was low and heterogeneous. Thus, expression of human agmatinase is altered in RCC. We discuss the consequences of these findings in terms of polyamine, NO metabolism and macrophage function. © 2003 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


The PTEN regulator DJ-1 is associated wi
✍ Raviprakash T. Sitaram; Claire J. Cairney; Pawel Grabowski; W. Nicol Keith; Beng 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 354 KB 👁 1 views

## Abstract DJ‐1 is as a novel regulator of the tumor suppressor PTEN with stimulatory effects on PI3K‐AKT/PKB signaling, one possible target of which is cMyc. The catalytic unit of the telomerase complex, hTERT, can be activated at different levels, including transcriptionally by cMyc and through

TYPE-1 PLASMINOGEN ACTIVATOR INHIBITOR I
✍ WAGNER, STEPHAN N.; ATKINSON, MICHAEL J.; THANNER, STEPHANIE; SCHMITT, MANFRED; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 597 KB

In experimental models, plasminogen activator-mediated degradation of the extracellular matrix is inhibited by type-1 plasminogen activator inhibitor (PAI-1). PA14 has also been shown to protect tumour stromal tissue from autoproteolytic activities and may thus substantially promote tumour growth an

Reverse transcriptase inhibitors induce
✍ Matteo Landriscina; Settimia Anna Altamura; Leonarda Roca; Margherita Gigante; A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 427 KB

## Abstract Reverse transcriptase (RT) inhibitors are emerging as a novel class of anticancer differentiating agents, active in several human tumor cell models, such as melanoma and prostate, thyroid and colon carcinoma. Indeed, much evidence suggests that they may act by inhibiting endogenous RT,

Activation of the MN/CA9 gene is associa
✍ Masaki Cho; Karin Grabmaier; Yoshiteru Kitahori; Yoshio Hiasa; Yoshinori Nakagaw 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 2 views

The MN/CA9 (G250) gene expressed in the normal alimentary tract in a tissue-specific manner is often activated in renal cell carcinomas. To cast light on the activation mechanism, we examined the methylation status of this gene in seven human renal cell carcinoma cell lines and three normal kidney t